Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hypertonic short-peptide enteral nutrition suspension is a specialized medical nutrition product designed for patients with severe impairment of digestive and/or absorptive function, such as those with incomplete gastrointestinal structure or function. It contains hydrolyzed whey protein (mainly di- and tri-peptides), medium-chain triglycerides, carbohydrates, vitamins, minerals, and other nutrients in a hypertonic suspension form. The formulation allows for direct absorption by the small intestinal mucosa without requiring extensive digestion[2][5]. Its primary clinical use is to provide enteral nutritional support to patients who cannot tolerate whole protein formulas due to malabsorption or digestive dysfunction. The product can be administered orally or via feeding tube (enteral route). Hypertonic formulations have higher osmolality than isotonic products and may increase the risk of diarrhea or gastric retention in some patients[1][6]. This type of preparation is typically fiber-free and lactose-free.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypertonic short-peptide enteral nutrition suspension.